Â
We help IVF clinics improve patient success rates through personalized and evidence-based nutritional optimization designed to support the metabolic, mitchondrial, gut, detoxification, and micronutrient status of your patients.Â
Â
Clinical Insights
The following goes through some of our key focus areas for optimization through targeted nutrition and supplementation that correlate strongly with better egg/sperm, embryo quality, and implantation rates. See end of page for relevant studies.Â
Thyroid Function
Targets: Free T3 ≥ 3.4 pg/mL
Reverse T3 < 12 ng/dL
TSH ≤ 2.5 mIU/L (with optimal Free T3)Thyroid antibodies (TPO/Tg): negative or within reference range.
Clinical relevance: Thyroid autoimmunity and peripheral thyroid dysfunction have been associated with lower implantation and higher miscarriage risk, even in euthyroid patients.
Metabolic Health (Glucose & Insulin)
FunctionalTargets: Fasting Insulin < 5 ÎĽIU/mL
Hemoglobin A1c ≤ 5.2%
Fasting Glucose 70–89 mg/dL.
Clinical relevance: Insulin resistance is linked to lower implantation, poorer oocyte/embryo quality, and increased early loss—even when conventional glycemic markers appear “normal.
Iron Recycling System
Targets: Ferritin 40-80 ng/ml, TSAT 25-35%, Normal hemoglobin and low inflammatory markers.
Clinical relevance: Iron is continually recycled through macrophages in the reticuloendothelial system. Inflammatory signals; common in endometriosis, autoimmune thyroid disease, and metabolic dysfunction disrupt this process by trapping iron in storage and generating excess free radicals. Excess oxidative stress and mitochondrial dysfunction reduce oocyte competence, impair embryo development, and are linked to implantation failure.
Methylation & Liver Pathways
Target: Homocysteine < 6 ÎĽmol/L. MCV (86-92), balanced folate/B12, ALT/AST ratio optimized
Clinical relevance: Efficient methylation supports DNA synthesis, hormone metabolism, and placental development. Elevated homocysteine reflects methylation inefficiency and has been linked to implantation failure, recurrent loss, and impaired placentation; optimized methylation supports hormone clearance and endometrial receptivity. Low or imbalanced folate/B12 can impair methyl-donor availability, alter endometrial receptivity, and increase oxidative stress. Liver enzyme patterns may reflect detox capacity that influences estrogen clearance and inflammatory tone.Â
Mitochondrial Health & Oxidative Stress
Target: hs-CRP <1 mg/L, GGT <20 U/L, Ferritin 40-80 ng/ml, Vitamin D 60-80 ng/ml
Clinical relevance: Mitochondria supply ATP for oocyte and sperm maturation, oxidative stress damages spindle formation and DNA integrity. Low-grade inflammation (CRP, GGT) and sub-optimal iron or vitamin D reduce mitochondrial efficiency. Optimizing these markers improves cellular energy production, fertilization potential, embryo quality, and improves implantation rates.
Vaginal & Gut Microbiome
Targets: Vaginal Lactobacillus dominance (e.g., L. crispatus/jensenii); low
abundance of pathogenic species (e.g., Gardnerella, Ureaplasma,
Mycoplasma). GI: balanced commensals and low inflammatory markers.
Clinical relevance: Non-Lactobacillus-dominant vaginal microbiota are associated with lower implantation and higher early loss; gut dysbiosis contributes to systemic inflammation and altered hormone metabolism.Â
Representative Case Outcomes
Case A — 36 YO, Endometriosis + Prior Miscarriage. After a failed transfer, patient completed pre-cycle optimization targeting thyroid antibodies, metabolic markers, and microbiome balance; subsequent retrieval + FET resulted in live birth (2025).
Case B — 39 YO, Autoimmune Disease + Multiple Failed Retrievals. After 8 years TTC, 5 retrievals, and a failed transfer, optimization of thyroid, methylation,
and microbiome preceded a successful pregnancy in the first cycle after working with our team. Due Spring 2026.
Case C — 35 YO, Graves Disease and Hyperthyroid. Could not try naturally due to vaginismus. Came to us after a successful retrieval to prep for her transfer. Transfer at month 3 with our team was a success and she is due in early 2026.Â
Case D — 34 YO, PCOS and early Insulin Resistance. Began IVF in month 4 with us and had a successful retrieval and fresh transfer that resulted in a live birth (2025).
Case E — 36 YO, Hypothyroid, history of loss. She came to us with secondary infertility after 3 failed IUIs. She prepped with our team and went through a retrieval and fresh transfer. Baby due in 2026.
The Science behind our approach
Disclaimer: The information presented on this website is intended for educational purposes only, and it hasn’t been evaluated by the Food and Drug Administration. This information isn’t intended to diagnose, treat, cure or prevent any condition or disease, nor is it medical advice. One should always consult a qualified medical professional before engaging in any dietary and/or lifestyle change.
